Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

HbA1c

Uncompromised HbA1c Results.

Published date: 3/8/2021 | Modified date: 6/9/2026

About HbA1c

Worldwide, 589 million adults are living with diabetes, and nearly half remain undiagnosed. Glycated hemoglobin (HbA1c) is a cornerstone marker for both diagnosing diabetes and monitoring long‑term glycemic control, as it reflects the average blood glucose level over the preceding three months.

More than 20  years ago, the WHO endorsed HbA1c as a diagnostic tool, establishing a threshold of 6.5% (48 mmol/mol).

Today, HbA1c testing remains essential for identifying diabetes and assessing disease progression in diagnosed patients.

Leveraging its extensive expertise in capillary electrophoresis, Sebia has optimized this high‑resolution technology for HbA1c analysis. This advanced method provides laboratories and clinicians with accurate, reliable, and clinically meaningful results, supporting improved patient care and long‑term disease management.

Key benefits

High‑resolution solution ensuring high‑quality results for all patients
  • Excellent separation

    The clear-cut and precise separation of the different hemoglobin fractions allows accurate HbA1c measurement thanks to high resolution separation of our capillary instruments.

  • Limited and visible analytical interferences

    There is no impact on HbA1c quantification in the presence of common analytical interferences—including labile A1c, carbamylated hemoglobin, Hb F, Hb S, Hb C, Hb D, and Hb E. The method also allows incidental detection of frequent hemoglobin disorders, such as sickle cell disease and β‑thalassemia. Thanks to the clear visual separation of hemoglobin fractions, potential interferences are minimized and flagged when present, ensuring results that are both reliable and clinically meaningful

  • Meaningful results

    By using the calculation formula from the IFCC reference method (HbA1c/(HbA1c+HbA0)), developed for the global harmonization of assays, the Sebia methodology ensures accurate and reliable results. Sebia CE does not produce erroneous results in samples containing homozygous hemoglobin variants or in patients lacking HbA, thereby providing laboratories and clinicians with great confidence in the results reported.

  • Adapted to each laboratory

    With Sebia’s broad portfolio of capillary electrophoresis instruments, laboratories can select the platform that best matches their workflow—from compact standalone benchtop systems to fully integrated workcell configurations

Main characteristics

Test principle

HbA1c corresponds to hemoglobin A that has undergone irreversible glycation on one or both N‑terminal valines of the β‑globin chains.

Its concentration reflects the integrated effect of glycemic fluctuations over the preceding weeks, providing a stable measure of long‑term glucose exposure.

HbA1c measurement is used:

  • To assess diabetes control, offering a reliable indicator of medium‑term treatment effectiveness.
  • As an aid in diagnosing diabetes mellitus and in identifying individuals at increased risk of developing the disease.

Sample type

  • Whole blood samples are used and analysed directly on Capillary instruments.
  • The Sebia CAPILLARY BLOOD SAMPLE KIT can be used on Capillary instrument and is an interesting alternative to venous blood sampling for HbA1c measurement.

Performances

                                         Throughput (tests/hour)*

HbA1c

  • CAPILLARYS 3 OCTA                  42
  • CAPILLARYS 3 TERA                   63
  • CAPILLARYS 3 TERA MC3**      185
  • MINICAP FLEX-PIERCING            8

No interference from common hemoglobin variants, or HbF or carbamylated hemoglobin. Factors that Interfere with HbA1c Test Results

*Firmware-dependent; contact your local Sebia representative for current information.
**Maximum Capacity or MC designation refers to Tube Loader CAPILLARYS 3 - P/N: 1249 and Rack Conveyor CAPILLARYS 3 - P/N: 1250 associated with CAPILLARYS 3 TERA - P/N: 1246.

Product details

Each Sebia capillary instrument has a dedicated reagent kit to perform HbA1c analysis.

  • CAPI 3 Hb A1c – P/N: 2515
  • MINICAP Hb A1c – P/N: 2215

Knowledge & Science

No content available.

HbA1c test can be performed on the following instruments

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.

Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.